Litacor (Leucovorin Calcium) is applied across key therapeutic domains to manage symptoms and provides crucial support in challenging clinical settings. Its primary uses include counteracting drug toxicity, treating certain cancers, and addressing specific anemias.

Supportive Therapy in High-Intensity Protocols

Litacor is commonly used for managing severe symptomatic patterns that arise from systemic drug toxicity, particularly following high-dose chemotherapy regimens. Its main benefit is providing a protective buffer to safeguard healthy tissues—like the bone marrow and gastrointestinal lining—from damage, and may help reduce the risk of life-threatening complications such as myelosuppression and severe mucositis that cluster during this acute treatment phase.

“Litacor provides support that helps ease the overall symptom burden when the body is subjected to intensive therapeutic agents.”

Enhancing Treatment for Advanced Malignancy

The medication is commonly used in combination with other anti-cancer drugs, such as fluorouracil, and is used to help with the therapeutic effect against malignant cells, especially in advanced colorectal cancer. This use is centered on the practical benefit of assisting in supporting clinical response and providing supportive relief during the management of progressive disease. Common clinical indications include the management of drug-induced toxicity, megaloblastic anemia due to folate deficiency, and use as an adjuvant in specific cancer therapies.

---

Quick Fact: Support in High-Stress Scenarios
Litacor assists with the symptomatic burden associated with physiological stress and symptomatic toxicity in acute treatment phases, contributing to a more stable experience during intensive therapeutic agents.

---

Correcting Deficiency-Driven Blood Disorders

Litacor is used for managing the symptomatic presentation of megaloblastic anemia caused by a folate deficiency when the patient cannot effectively absorb or utilize standard oral folate. It provides a readily available factor necessary to assist with supporting blood cell function, offering a key benefit that helps ease related symptoms such as fatigue and overall systemic weakness.

Specialized Management of Neurological Symptoms

In highly specific, rare conditions like Cerebral Folate Deficiency (CFD), Litacor may be applied to address the complex neurological symptoms resulting from impaired folate transport into the brain. Its use aims to provide essential metabolic support, with the therapeutic benefit of potentially assisting with supporting developmental stability and managing symptoms such as seizures and motor coordination challenges in affected patient groups.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Litacor?

The official regulatory profile for Litacor (Leucovorin Calcium) strictly defines population eligibility based on absolute prohibitions and conditional requirements.

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults for all standard labeled uses, including Leucovorin Rescue.
• Pediatric patients for specific established indications.
• Patients with megaloblastic anemia due to folate deficiency.

Populations for whom use is contraindicated:

• Hypersensitivity to Litacor or any component of the formulation.
• Pernicious Anemia or other megaloblastic anemias caused by Vitamin B12 deficiency.
• Intrathecal administration (injection into the spinal fluid) is strictly prohibited.

Age-related eligibility rules:

• Older adults require caution, particularly when receiving combination therapy with 5-Fluorouracil, due to an increased risk of severe toxicity.

Condition-specific eligibility rules:

• Impaired renal function requires careful monitoring, as delayed elimination may necessitate adjustment of the rescue treatment duration.
• Combination use with 5-Fluorouracil must not be initiated or maintained in patients with unresolved severe gastrointestinal toxicity.

Pregnancy and lactation eligibility status (if explicitly documented):

• Pregnancy: Use is generally limited to situations where it is clearly needed.
• Lactation: Caution is required; combination therapy with 5-Fluorouracil is not recommended while breastfeeding.

---

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents):

• Contraindicated: Hypersensitivity, Vitamin B12 deficiency anemia, Intrathecal Route.
• Not Recommended: Combination use in Lactation.
• Use with Caution: Older Adults, Impaired Renal Function.

Connection to the overall eligibility profile (2–4 sentences): The eligibility profile is defined by a hierarchy of official regulatory statements, ranging from absolute prohibitions (contraindications) for hypersensitivity and Vitamin B12 deficiency, to specific cautions for older adults and those with organ function impairment. These classifications explicitly define the populations that can or must not use the medicine, according to government labeling standards.

Interactions with other medicines and products

This section summarizes the officially documented interaction patterns of Litacor (Leucovorin Calcium) as described in government regulatory sources.

---

Documented Interaction Patterns

Interacting Substance	Official Regulatory Statement Summary
Fluorouracil (5-FU) and prodrugs	Enhances the toxicity of 5-FU, particularly severe gastrointestinal toxicities, including diarrhea and stomatitis.
Antiepileptic Drugs (Phenytoin, Phenobarbital)	May counteract the antiepileptic effect and is associated with an increased risk of seizure frequency.
Trimethoprim-Sulfamethoxazole	Associated with increased rates of treatment failure and morbidity when used for acute Pneumocystis treatment in HIV patients.
Glucarpidase	Significantly decreases serum concentrations of the active metabolite of leucovorin.

---

Official Administration Restrictions

Certain constraints and timing rules are mandated by regulatory agencies to manage interaction risks:

• Physical Restriction: Litacor and Fluorouracil must not be mixed in the same intravenous infusion solution due to the risk of forming a physical precipitate.
• Timing Separation: Administration of Litacor must be avoided within 2 hours of receiving Glucarpidase to account for the clearance of leucovorin’s active metabolite.
• Population Note: Elderly patients are identified as having a greater risk for severe gastrointestinal toxicity during the weekly co-administration regimen with Fluorouracil.

Interactions with Food, Alcohol, or Herbal Products: No specific interactions with food, alcohol, or herbal products are officially documented in the main regulatory labels.

How Litacor Works

The mechanism of action for Litacor (Leucovorin Calcium) is defined by two distinct pharmacodynamic effects: functional replacement and enzyme stabilization.

Metabolic Bypass and Functional Rescue

Litacor functions as a substrate replacement, supplying the body with pre-reduced, active folate cofactors that bypass the need for the Dihydrofolate Reductase (DHFR) enzyme. This mechanism provides essential cofactors necessary for the synthesis of DNA and RNA, supporting cellular turnover in tissues with high proliferation rates, such as bone marrow cells.

Cofactor-Mediated Enzyme Modulation

In a separate, context-dependent mechanism, Litacor's active metabolite, 5,10-methylenetetrahydrofolate, functions as an allosteric stabilizer for the Thymidylate Synthase (TS) enzyme. By enhancing the binding affinity of certain co-administered anti-metabolites, it locks the enzyme into a stable, inhibited complex. This results in the intensification of enzymatic inhibition, leading to a targeted depletion of DNA precursors.

Litacor (Leucovorin Calcium) is utilized through specific administration patterns that differ based on the clinical context. It is available as an oral tablet and a solution or powder for injection for systemic administration via the intravenous (IV) or intramuscular (IM) route. The intrathecal route is explicitly contraindicated.

---

The choice of administration route is governed by dosage and clinical condition. Oral administration is generally limited to doses of approximately 25 mg or less due to the risk of saturable absorption. The parenteral route (IV or IM) is typically required for higher doses or in patients experiencing gastrointestinal issues that might compromise absorption.

---

Dosing is strictly scheduled. For example, in Methotrexate Rescue protocols, a standard dose of 15 mg (or 10 mg/m^2) is repeated every 6 hours for a defined number of doses, with the total duration determined by the patient’s serum Methotrexate concentration. In contrast, use alongside 5-fluorouracil for advanced malignancy protocols follows a cyclic schedule, typically involving administration for five consecutive days, repeated after a recovery interval.

Specific procedural constraints are observed for injections. The intravenous injection rate is limited to a maximum of 160 mg per minute due to the calcium content of the solution. Furthermore, the prepared solution is not physically mixed with 5-fluorouracil due to precipitation risk. Dosage adjustments are also defined for specific populations; for instance, the duration of use is often prolonged or increased in patients who exhibit delayed elimination due to impaired kidney function.

Research Evidence / Overview of Studies for Litacor

---

Evidence for Use as a Rescue Agent in High-Dose Methotrexate Protocols

Litacor was studied for its role as a rescue agent primarily through non-comparative clinical studies and regulatory data based on established clinical experience. Research explored the application of Litacor in adult and pediatric patients with various cancers who were receiving high-dose methotrexate (HDMTX) chemotherapy. Outcomes monitored included specific physiological changes in cell counts and mucous membrane condition, as well as the body's physiological strain following the intensive treatment.

The research examined how quickly the body eliminated methotrexate from the bloodstream, a key biomarker for toxicity risk. Studies reported measurements of blood cell function observed during the study period following the high-intensity therapy. This practice is widely recognized in the context of high-dose MTX protocols.

Evidence for Combination Use in Advanced Colorectal Cancer

The evidence supporting the combination use of Litacor in advanced colorectal cancer was evaluated in numerous Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews and Meta-analyses. These studies included adults with metastatic disease and focused on comparing a regimen that combined Litacor with the chemotherapy drug fluorouracil (5-FU) against regimens using 5-FU alone.

Research examined long-term outcomes, including metrics like Overall Survival and Progression-Free Survival, which describe the time until disease progression. Trials also monitored the objective Tumor Response Rate, a measure of tumor size change. Studies reported measurements of overall survival and tumor size observed when the combination of Litacor and 5-FU was compared against 5-FU as a single agent.

Research Gaps and What Remains Uncertain About Litacor

Research examined patterns related to rare conditions like Cerebral Folate Deficiency (CFD), but the evidence for these uses is characterized by modest sample sizes and study heterogeneity, meaning more data are still emerging and certainty remains low for outcomes in broader patient groups.

For most uses, the evidence quality varies across studies, with complex combination therapies being supported by large RCTs, while deficiency-based uses rely more on clinical consensus and metabolic data. The optimal administration of Litacor in conjunction with modern treatment protocols is an area of ongoing research.

Key Studies & References

1. Folinic Acid - StatPearls (NCBI Bookshelf)
2. leucovorin calcium injection, usp (Health Canada Product Monograph)

Common questions about Litacor (FAQ)

Q: Can children or older adults take this medicine?

Official product information states that Litacor is described in regulatory documents as being used in adults and pediatric patients (children) for specific, established indications. Caution is advised for older adults, particularly when this medicine is used in combination with fluorouracil, due to an increased risk of severe gastrointestinal side effects.

---

Q: Why can't Litacor be used for Vitamin B12 deficiency anemia?

Leucovorin is considered improper therapy for megaloblastic anemia if the cause is a Vitamin B12 deficiency. Regulatory documents state that it may provide benefit to the blood disorder while potentially masking the ongoing progression of neurological damage associated with B12 deficiency.

---

Q: Does Litacor come in a capsule or a liquid for drinking?

According to the official product labeling, Litacor is supplied as an oral tablet, a solution for injection, and a powder for injection. The official product labeling lists no capsule form or any specific oral liquid formulation designed for drinking.

---

Q: Is there any research on Litacor's use in Cerebral Folate Deficiency?

Regulatory reviews mention that research has examined patterns related to rare conditions like Cerebral Folate Deficiency (CFD). However, the evidence is often described as involving small study groups and varied results, meaning certainty remains low for outcomes in broader patient groups.

---

Q: How will my doctor know what dose of Litacor I need?

Official prescribing information indicates that the dose and treatment duration for Litacor are strictly scheduled and governed by the clinical context. For example, in certain rescue protocols, the dosing schedule is adjusted based on monitoring the concentration of other medicines in your blood and checking signs of kidney function.

---

Q: Is Litacor a type of chemotherapy drug?

Official sources classify Litacor (Leucovorin Calcium) primarily as a Folate Analogue, and functionally as an Antidote or Rescue Agent. Its main purpose is as an adjunctive therapy designed to counteract the toxic effects of certain other medications, such as folic acid antagonists, on healthy, rapidly dividing cells.

---

Q: What storage temperature is required for the tablets?

Regulatory documents state the tablets should be stored at a Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The medicine must also be kept protected from both moisture and light.

How to Store and Dispose of Litacor (Leucovorin Calcium)

Official regulatory documents define specific conditions for the storage, stability, and disposal of Litacor.

Storage Requirements

Temperature and Protection: The unreconstituted product must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The medicine must be protected from light and should be kept from freezing. Tablets must also be protected from moisture. The product must be kept out of the sight and reach of children.

Stability Constraints: Once the powder is reconstituted, its stability is time-limited. Solutions made without a preservative must be used immediately, while solutions containing a preservative typically must be used within 7 days. The drug must not be mixed with 5-fluorouracil due to the risk of precipitate formation.

Disposal Instructions

Product and Sharps: Unused or expired medication must be discarded according to local pharmaceutical waste procedures. Used needles and syringes associated with the injection form must be placed immediately in an FDA-cleared sharps disposal container.